The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Peter Rossing MD DMSc is the Head of Complications Research, Chief Physician, Steno Diabetes Center Copenhagen, Denmark.
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.
Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
He is coordinator of the EU FP7 project PRIORITY demonstrating that urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.
He has co-authored >450 papers and his h-index is 73. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry
Roland E. Schmieder
University Hospital Erlangen, Erlangen , Germany
Professor Schmieder is currently Professor of Internal Medicine, Nephrology and Hypertension and Head of the Clinical Research Center of Hypertension and Vascular Medicine (www.crc-erlangen.de) at the Department of Nephrology and Hypertension, University Hospital Erlangen, Germany. Prof. Schmieder has extensive experience in the execution of clinical observational and international multicenter studies.
His research interests include hypertension, vascular medicine, nephrology and non-invasice cardiology, with the focus on organ damage to the heart, kidneys, arteries and retinal circulation and its treatment. He directs the Institute of Preventive Medicine in Germany (www.ipm-aktuell.de) that transfers new evidence to health care providers (physicians, nurses) and patients.
Hebrew University of Jerusalem, Jerusalem, Israel
Ofri Mosenzon is Manager of the Diabetes Clinical Research Center at the Hadassah Hebrew University Hospital, Jerusalem, Israel, where she also teaches Endocrinology, Internal Medicine and Epidemiology. Dr Mosenzon received her medical degree from the Faculty of Medicine, Technion, Haifa, Israel. She is board-certified in Internal Medicine and Endocrinology, and has an MSc in Clinical Epidemiology from the Hebrew University, Jerusalem.
Since 2010, Dr Mosenzon has been the Principal Investigator of more than 30 phase 2, 3 and 4 clinical trials in the fields of diabetes, diabetic treatments, diabetic complications (nephropathy, retinopathy and neuropathy), cardiovascular endpoints, obesity and hyperlipidaemia. She has initiated, planned and executed clinical research projects that were funded independently from industry. Dr Mosenzon has been involved in the planning, execution and summarising of several large-scale international trials, including Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58.
Dr Mosenzon’s self-initiated research interests include, but are not limited to, glucagon-like peptide-1 receptor analogues, training family physicians as diabetologists, fear of hypoglycaemia, predictive value of normal fasting glucose levels, and diabetes among different ethnic groups and minorities in Israel. She has led many peer-reviewed publications, books, chapters and poster presentations. She is a member of the European Association for the Study of Diabetes, the American Diabetes Association, the Israeli Diabetes National Council, the Israel Association for Endocrinology, and the Israel Diabetes Association.
Hiddo L. Heerspink
University Medical Center Groningen, Groningen, Netherlands
Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen.
Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with chronic kidney disease with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce kidney and cardiovascular complications of chronic kidney disease. His main expertise includes clinical trial design, personalized medicine as well as methodological aspects and statistical analyses of clinical trials.
Professor L. Heerspink has authored and co-authored over 350 peer-reviewed publications and is editorial board member of Diabetes Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Pharma, Janssen, Fresenius, Gilead Sciences, Merck, Mitsubishi Tanabe, Mundi Pharma and Retrophin.